Search
Search Results
-
Wild-type IDH1 inhibition enhances chemotherapy response in melanoma
BackgroundAlternative treatment strategies in melanoma beyond immunotherapy and mutation-targeted therapy are urgently needed. Wild-type isocitrate...
-
Wild-type IDH1 Knockout Leads to G0/G1 Arrest, Impairs Cancer Cell Proliferation, Altering Glycolysis, and the TCA Cycle in Colon Cancer
The isocitrate dehydrogenase (IDH), which participates in the TCA cycle, is an important key enzyme in regulating cell metabolism. The effect of the...
-
Flavopiridol Suppresses Cell Proliferation and Migration and Induces Apoptotic Cell Death by Inhibiting Oncogenic FOXM1 Signaling in IDH Wild-Type and IDH-Mutant GBM Cells
Glioblastoma multiforme (GBM) remains one of the most challenging solid cancers to treat due to its highly aggressive and drug-resistant nature....
-
IDH1 mutation is detectable in plasma cell-free DNA and is associated with survival outcome in glioma patients
BackgroundCirculating cell-free DNA (cfDNA, liquid biopsy) is a powerful tool to detect molecular alterations. However, depending on tumor...
-
Synergy between TMZ and individualized multimodal immunotherapy to improve overall survival of IDH1 wild-type MGMT promoter-unmethylated GBM patients
The prognosis of IDH1 wild-type MGMT promoter-unmethylated GBM patients remains poor. Addition of Temozolomide (TMZ) to first-line local treatment...
-
Comprehensive analysis of the REST transcription factor regulatory networks in IDH mutant and IDH wild-type glioma cell lines and tumors
The RE1-silencing transcription factor (REST) acts either as a repressor or activator of transcription depending on the genomic and cellular context....
-
Exceptionally rare IDH1-mutant adult medulloblastoma with concurrent GNAS mutation revealed by in vivo magnetic resonance spectroscopy and deep sequencing
Medulloblastoma (MB) is the most common malignant brain tumor occurring in childhood and rarely found in adults. Based on transcriptome profile, MB...
-
Loss of H3K27 trimethylation is frequent in IDH1-R132H but not in non-canonical IDH1/2 mutated and 1p/19q codeleted oligodendroglioma: a Japanese cohort study
Oligodendrogliomas are defined by mutation in isocitrate dehydrogenase (NADP(+)) ( IDH )1/2 genes and chromosome 1p/19q codeletion. World Health...
-
Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial
Vorasidenib and ivosidenib inhibit mutant forms of isocitrate dehydrogenase (mIDH) and have shown preliminary clinical activity against m IDH glioma....
-
Pharmacogenomic profiling reveals molecular features of chemotherapy resistance in IDH wild-type primary glioblastoma
BackgroundAlthough temozolomide (TMZ) has been used as a standard adjuvant chemotherapeutic agent for primary glioblastoma (GBM), treating isocitrate...
-
SIRT7–SREBP1 restrains cancer cell metabolic reprogramming by upregulating IDH1
SIRT7 plays critical roles in tumorigenesis and tumor progression; however, the underlying mechanisms are poorly understood. Here, we aimed to...
-
Classification of IDH wild-type glioblastoma tumorspheres into low- and high-invasion groups based on their transcriptional program
BackgroundGlioblastoma (GBM), one of the most lethal tumors, exhibits a highly infiltrative phenotype. Here, we identified transcription factors...
-
The diagnostic value of lower glucose consumption for IDH1 mutated gliomas on FDG-PET
BackgroundNon-invasive diagnosis of IDH1 mutation for gliomas has great clinical significance, and PET has natural advantage to detect metabolism, as...
-
Identification and characterization of isocitrate dehydrogenase 1 (IDH1) as a functional target of marine natural product grincamycin B
Grincamycins (GCNs) are a class of angucycline glycosides isolated from actinomycete Streptomyces strains that have potent antitumor activities, but...
-
REGISTRI: Regorafenib in first-line of KIT/PDGFRA wild type metastatic GIST: a collaborative Spanish (GEIS), Italian (ISG) and French Sarcoma Group (FSG) phase II trial
BackgroundApproximately 15% of adult GIST patients harbor tumors that are wild-type for KIT and PDGFRα genes (KP-wtGIST). These tumors usually have...
-
IDH mutations in G2-3 conventional central bone chondrosarcoma: a mono institutional experience
BackgroundHeterozygous isocitrate dehydrogenase ( IDH ) mutations occur in about half of conventional central bone chondrosarcomas (CCBC). Aim of this...
-
Clinical significance of histopathological features of paired recurrent gliomas: a cohort study from a single cancer center
ObjectiveTo explore the histopathological characteristics of paired recurrent gliomas and their clinical significance.
MethodsGlioma patients who...
-
A genetic model for central chondrosarcoma evolution correlates with patient outcome
BackgroundCentral conventional chondrosarcoma (CS) is the most common subtype of primary malignant bone tumour in adults. Treatment options are...
-
Dissection of transcriptomic and epigenetic heterogeneity of grade 4 gliomas: implications for prognosis
BackgroundGrade 4 glioma is the most aggressive and currently incurable brain tumor with a median survival of one year in adult patients. Elucidating...
-
IDH-wild type glioblastomas featuring at least 30% giant cells are characterized by frequent RB1 and NF1 alterations and hypermutation
Giant cell glioblastoma (GC-GBM) is a rare variant of IDH -wt GBM histologically characterized by the presence of numerous multinucleated giant cells...
